Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial.

ABSTRACT:

Background

Refractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation. Long-term survival is mainly influenced by complete remission (CR) rates after induction therapies.

Objectives

To investigate CR/CR with incomplete hematologic recovery (CRi) rates and adverse events with a new induction therapy (bortezomib, homoharringtonine, and cytarabine [BHA]) for patients with R/R AML.

Methods

We enrolled 21 patients with R/R AML (median age, 42 [range, 30-62] years), who received BHA for remission induction (bortezomib, 1.3 mg/m²/day on days 1 and 4; homoharringtonine, 4 mg/m²/day for 5 days, and cytarabine, 1.5 g/m²/day for 5 days). CR and adverse events were

SUBMITTER: Zhang C 

PROVIDER: S-EPMC10472935 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature